1 Stock Quietly Crushing It 💪
A silent sleeper poised to skyrocket? 🚀
Note: Please read our disclaimer at the bottom of the article.
#ATG 🙌 #BOP 🚀 Nation Update❤️️
Hi, I’m Paul Mampilly.
Welcome to my company's Substack, where we provide daily coverage of #OGI (opportunity, growth, and innovation) market trends, macro level analysis, and stock picks.
Like our name suggests, at ATG Digital, we go Against the Grain to support everyday people on their investing journeys.
ATG also represents seeing the world for what is abundantly clear to see — an opportunity for incredible growth and the BRIGHT and PROSPEROUS future that lies ahead.
To aid you on your journey to financial freedom, we have five paid plans starting at $9.99 for you to consider.
With a subscription you get:
Premium Content: Weekly market and stock updates via email.
Stock Picking Guidance: Flash (buy/sell) alerts.
Model Portfolio Access: Access to LIVE portfolios.
Webinars: Private events with the team selected by you.
Just visit atgdigital.media to see which plan is the best fit for your journey!
Substack 🥞 subscribers: 6,294
Dan: Don’t Sleep on the Quiet Movers 🤫
With Bitcoin USD (BTC-USD) making new all-time highs and gold and silver surging, it's easy to get caught up in the headlines.
But behind the scenes, lesser-known stocks are quietly heating up.
These quiet movers could yield significant gains — if you know where to look.
In parts of the market, heavy selling has crushed stock prices.
Retail traders generally chase trends, driven more by emotion than strategy.
They often panic and sell into dips, causing an even further sell-off.
With so many retailers flooding the markets, short-term trend following has reached extreme levels.
Household names like NVIDIA Corporation (Nasdaq: NVDA) and Microsoft Corporation (Nasdaq: MSFT) continue hitting new highs.
But be careful!
In our opinion, this is retail buying at a likely top while institutions exit.
On average, retailers buy near highs and sell near lows.
Companies such as NVDA 0.00%↑ and MSFT 0.00%↑ have sky-high expectations — and we wouldn’t be surprised if earnings guidance for many companies disappoint.
So, where could you invest in this tricky, choppy environment?
One high-growth opportunity on our radar comes from the biotech sector . . . 👇
Where Smart Money Looks 👀
We hold Rhythm Pharmaceuticals Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company, in our Gold Tier model portfolio.
RYTM 0.00%↑ is developing and commercializing therapies for rare genetic obesity diseases.
Its lead product, Imcivree, is approved for chronic weight management in patients with specific genetic deficiencies.
But the bigger opportunity could be with its new oral drug, bivamelagon, targeting acquired hypothalamic obesity — a rare but serious condition with significant unmet medical need.
Jaw-Dropping Trial Results 😮
Earlier this week, RYTM 0.00%↑ released Phase 2 data results for bivamelagon.
Let’s review the highlights . . .
Patients taking 600mg of the drug achieved 9.3% (Body Mass Index) BMI reductions.
Those taking 400mg dosage saw reductions of 7.7% within 14 weeks.
Patients taking the placebo saw a BMI increase of 2.2%.
With these results, the company is moving forward with U.S. and EU regulators to prepare for Phase 3 trials designed to advance the treatment.
It also plans to request an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and to seek scientific advice from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
That said, momentum is building fast.
So, what does this mean for investors?
The Future Looks Promising 🤩
When the trial results dropped, on Wednesday, the stock price jumped 35% in a single day!
But here’s the kicker: just a month ago when biotech was selling off and sentiment was low, that same news might have been ignored or even sold off.
In fact, we wouldn’t have been surprised to see the stock price drop 35% on the same news then.
But now, we believe the tide has turned for biotech!
In our opinion, the sector is showing extreme strength.
Major retail selling is likely behind us, and many companies are still trading at relatively low valuations.
Although RYTM 0.00%↑ trades at all-time highs, we believe there's plenty more room to run.
It’s still a small company ($5 billion market cap) with two potential blockbuster drugs.
Both could generate substantial revenue and push the stock’s price much higher.
We’re currently up 80% on our position — with no plans to sell anytime soon.
With biotech bouncing off sector lows, we’re leaning in across our ATG Digital portfolios.
Earlier this week, in our Platinum Tier, we added a call option on a biotech company we believe could soar.
It’s currently trading at an extremely low valuation with massive upside potential.
If our thesis plays out, this could easily become a triple-digit winner, in our view.
To see this bet — and other high-upside opportunities in our Platinum Tier options portfolio — click here.
Unlock More Potential Winners 🏁
Biotech is back and on fire. 🔥
And while most investors chase the noise, at ATG Digital, we’re stacking potential game-changers in several overlooked sectors.
Curious to see what’s in our high-conviction lineup — and what we’re buying next?
Click the button below to discover our edge with the Gold Tier model portfolio.
P.S. As a Gold Tier member, you could enjoy:
✅ Weekly portfolio commentary
✅ Real-time trade alerts (email + SMS)
✅ Full access to our model portfolio
✅ High-conviction ideas built on expert research
✅ Answers to your questions
#OGI100: Friday, July 11, 2025
The #OGI100 is up 1.11% today.
Created on September 22, 2022, the #OGI100 is an index/portfolio comprised of opportunity, growth, innovation, and crypto-related investments.
Our goals with the #OGI100 are twofold . . .
First, we want readers to get a sense of what our investments are doing in the market, because they can sometimes perform very differently than traditional indices (like the S&P 500 or Nasdaq 100).
Second, we’d like to eventually turn the #OGI100 into an exchange-traded fund (ETF).
That way, instead of owning hundreds of growth stocks, you can get exposure to ATG Digital thinking — in opportunity, growth, innovation, and crypto — all in one place.
To learn more or to express your support for the launch of an ETF (by completing a poll), click here.
Next week: Paul reveals warning signs for a potential turning point in the market. ⚠️
Rewind the Week With ATG Digital!
Did you miss our other Substacks this week? Don’t worry.
You can catch up on them below:
Tuesday — 1 Company Farming Serious Growth 🚜
Wednesday — Jackpot Play! 🤑 We Called It Here.
Thursday — Our Very First OGI100 Review 👀
On Friday, July 11, 2025, let us know below which Substack was your favorite!
❤️ This Substack was made — by US, for YOU — with love. ❤️
Questions? Concerns? 🤔 Look Below 👇
Have questions or trouble accessing your account? Please reach out to us at info@atgdigital.media or schedule a call, and our Customer Support team will be happy to help.
You can also check our FAQ page on our website for an up-to-date list of questions and answers. Your question may have been addressed there.
*Please be advised that customer support calls are limited to 15 minutes and will strictly cover your membership subscription and billing needs only. Any calls that are disrespectful in nature may be subject to immediate termination.
Join us, be #BOP 🚀, be #StrongHands 🙌, #GoATG! ️️❤️️
Disclaimer/Legal Stuff Written in Plain English
What you read/watch/hear is OPINION, not financial/investment advice. Treat it no different than when you read/watch/hear your favorite author/YouTuber/podcaster. Despite our best efforts, we get things wrong and make mistakes. Investing is risky. There is no guarantee you will make money. Your investments may lose value. That’s RISK. Past performance is no guarantee of future results. Employees, contractors, and owners of ATG Digital, LLC own/trade/transact in the stocks, options, and crypto that are the subject of our trade alerts, updates, reports, and commentaries. We cannot give you personalized financial advice because we are NOT financial advisors. It’s on you to decide how much/when/what to buy/sell based on YOUR financial needs, plans, and risk preferences. There are no guarantees. Loss of your capital is an outcome that you should evaluate carefully with a financial advisor before you trade, speculate, or invest. It's your money and your responsibility.